VALANX
1 known investors
VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites. It targets biopharma developers building next-generation ADCs, aiming to widen therapeutic windows and reduce off-target toxicity.
Founders & leadership
ML
Michael LukeschCEO & Founder
GA
Georg AltenbacherCBO & Co-Founder
KO
Klaus OrlingerChief Scientific Officer
Investors Β· 1
Frequently asked questions
- What does VALANX do?
- VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites. It targets biopharma developers building next-generation ADCs, aiming to widen therapeutic windows and reduce off-target toxicity.
- Who founded VALANX?
- VALANX was founded by Michael Lukesch, Georg Altenbacher.
- Who are VALANX's investors?
- VALANX's investors include xista science ventures.